BioSpace News Archive

Stealth BioTherapeutics Corp today announced that it will report third quarter 2021 financial results on Thursday, November 11 , before the market opens.

MDxHealth SA announced the pricing of its initial public offering in the United States of 3,750,000 American Depositary Shares at a price to the public of USD 12.00 per ADS1 for total gross proceeds of USD 45.0 million2 before deducting underwriting discounts and commissions and estimated offering expenses.

Orchard Therapeutics today reported financial results for the quarter ended September 30, 2021, as well as recent business updates and upcoming milestones.

Kymera Therapeutics, Inc. announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually, and at the 63rd American Society of Hematology Annual Meeting, taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.

Protara Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

Eyenovia, Inc., an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, announced that the first patient has been enrolled in the Company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in near vision, known as VISION-2.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences.

Lipocine Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis (“NASH”). LPCN 1144

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments for its third quarter ended September 30, 2021.